France · Delayed Price · Currency is EUR Neovacs Company Description
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies.
IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies.
The company was founded in 1993 and is based in Suresnes, France.
| Country | France |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Hugo Brugiere |
Contact Details
Address: 14 Rue de la Republic FR Suresnes, 92150 France | |
| Phone | 33 1 53 10 93 00 |
| Website | neovacs.com |
Stock Details
| Ticker Symbol | ALNEV |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR00140077X1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hugo Brugiere M.Sc. | Chairman, GM and Chief Executive Officer |
| Prof. Daniel Zagury M.D., Ph.D. | Founder, Chairman of Scientific Research Committee and Director |
| Vincent Serra Ph.D. | Scientific and Operational Director |
| Alexandre Courtoux | Administrative and Financial Director |
| Charlene Masson | Corporate Communication and Investor Relations |
| Bernard Fanget | Vice President of Pharmaceutical Affairs and Director |